Alkermes (NasdaqGS:ALKS) just posted third quarter 2026 results that combined higher revenue with sharply lower profit, as the business swung to a loss over the first nine months of the year.
Alkermes shares have climbed strongly this year, with a year-to-date share price return of 66.42% and a 1-month share price gain of 14.10%, suggesting positive momentum despite a 90-day share price decline of 5.66% around the weaker profit figures.
Scan how Alkermes compares with other biopharma stocks showing strong price and fundamentals momentum using this curated list of 19 high quality undiscovered gems.
After a 66% year-to-date surge and a swing from profit to loss over nine months, Alkermes now asks a simple question of investors: Do the current valuation and risk still lean in favor of buyers?
Alkermes closed at $47.03, while the analyst consensus Narrative on Simply Wall St sets fair value at $56.56 using an 8.47% discount rate. This frames the current price as meaningfully below that estimate and puts the orexin pipeline at center stage.
The main requirement is that Alkermes converts encouraging alixorexton and ALKS 7290 data into successful late stage trials, regulatory approvals and commercial adoption, while managing higher R&D spending and integration of the LUMRYZ business.
The current valuation implies investors are already pricing in meaningful success for the orexin platform and LUMRYZ expansion, even as Alkermes is guiding to a GAAP net loss in 2026 alongside positive EBITDA.
See why 9 investors see Alkermes as 17% undervalued.
Result: Fair Value of $56.56 (UNDERVALUED)
Still, the Alkermes thesis hinges on successful orexin and LUMRYZ trial outcomes, while higher R&D spending and a guided GAAP net loss in 2026 remain pressure points.
Find out about the key risks to this Alkermes narrative.
If this all feels optimistic on Alkermes, treat it as a prompt to test the assumptions yourself and act quickly to form your own stance. Then pressure test that early view against the 3 key rewards.
Do not stop your research with Alkermes. Use the Simply Wall St screener to hunt for other ideas that match your risk tolerance and return goals while this cycle plays out.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com